ATS View
한국어

Dae Hwa Pharm KRX:067080KOSDAQ

대화제약 · Korean news coverage and regulatory filings, organized.

한국어
Articles, 24h2
Articles, 7 days3
DART filings, 7 days0
Articles tracked39since Sep 11

In Q2 2026, Dae Hwa Pharm reported revenue of ₩41.3bn, up 14.8% year on year, and operating profit of ₩3.3bn. Dae Hwa Pharm (대화제약) appeared in 3 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Oct 22 with 5 articles. The most common catalyst was tech & capacity (1).

Filing signals Insider selling Screener

Dae Hwa Pharm quarterly results consolidated, KRW

QuarterRevenueYoYOperating profitNet income
Q2 2026₩41.3bn+14.8%₩3.3bn
margin 8.1%		₩2.0bn
Q1 2026₩37.0bn+1.0%₩454m
margin 1.2%		−₩266m
Q4 2025 derived₩33.7bn-16.0%₩699m
margin 2.1%		₩3.3bn
Q3 2025₩36.7bn+2.6%₩1.0bn
margin 2.9%		−₩179m
Q2 2025₩36.0bn-7.3%₩285m
margin 0.8%		−₩517m
Q1 2025₩36.7bn+5.7%₩1.1bn
margin 3.1%		−₩297m
Q4 2024 derived₩40.1bn+4.2%₩3.4bn
margin 8.6%		₩1.4bn
Q3 2024₩35.8bn+1.3%₩1.7bn
margin 4.7%		₩218m

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

Dae Hwa Pharm top stories 2 weeks, by number of outlets

  1. 1
    대화제약, 강원대 약대와 ‘제약∙바이오 우수인재 양성’ 업무협약
    4 outlets · 4 articlesFirst report Oct 22 09:34 라포르시안
  2. 2
    대화제약-강원대, 제약·바이오 인재 양성·공동 연구 맞손
    1 outlets · 1 articlesFirst report Oct 22 10:07 히트뉴스Partnership
  3. 3
    대화제약·강원대 약대, 제약·바이오 인재 양성 협약
    1 outlets · 1 articlesFirst report Oct 23 19:39 메디포뉴스
  4. 4
    대화제약, 생산혁신 리더십 인정...국가생산성대회 대상
    1 outlets · 1 articlesFirst report Oct 30 12:00 팜뉴스
  5. 5
    대화제약, 국가생산성대회 리더십 대상…DPS 기반 스마트팩토리 추진
    1 outlets · 1 articlesFirst report Oct 30 12:21 메디코파마

Latest Dae Hwa Pharm news Korean headlines